OMERS ADMINISTRATION Corp Raises Stock Position in Pfizer Inc. $PFE

Key Points

• OMERS ADMINISTRATION Corp increased its stake in Pfizer Inc. by 42.4%, holding 344,122 shares valued at approximately $8.72 million after acquiring an additional 102,442 shares.
• Pfizer's stock has experienced a range between a 12-month low of $20.92 and a high of $30.43, currently trading at $25.08 with a market capitalization of $142.57 billion.
• The company announced a quarterly dividend of $0.43 per share, yielding 6.9% on an annualized basis, with a payout ratio of 91.49%.

OMERS ADMINISTRATION Corp raised its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 42.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 344,122 shares of the biopharmaceutical company's stock after acquiring an additional 102,442 shares during the period. OMERS ADMINISTRATION Corp's holdings in Pfizer were worth $8,720,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of the business. Brighton Jones LLC lifted its position in Pfizer by 1,282.4% during the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company's stock worth $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its stake in Pfizer by 12.5% in the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company's stock valued at $498,000 after purchasing an additional 2,087 shares during the last quarter. Utah Retirement Systems increased its stake in Pfizer by 0.3% in the fourth quarter. Utah Retirement Systems now owns 940,568 shares of the biopharmaceutical company's stock valued at $24,953,000 after purchasing an additional 2,800 shares during the last quarter. Voleon Capital Management LP acquired a new position in shares of Pfizer in the 4th quarter valued at $2,120,000. Finally, Kapitalo Investimentos Ltda acquired a new position in Pfizer during the fourth quarter valued at approximately $89,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

PFE has been the subject of several analyst reports. Jefferies Financial Group upped their target price on Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research report on Wednesday, May 21st. HSBC decreased their price target on Pfizer from $27.00 to $26.00 and set a "buy" rating for the company in a report on Monday, May 19th. UBS Group boosted their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Redburn Atlantic lowered their price target on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a report on Wednesday, April 30th. Finally, Leerink Partners cut their price objective on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a report on Wednesday, April 30th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus price target of $28.12.

Pfizer Stock Performance

Shares of PFE opened at $25.08 on Thursday. The stock has a market capitalization of $142.57 billion, a PE ratio of 13.34, a price-to-earnings-growth ratio of 0.89 and a beta of 0.52. Pfizer Inc. has a 12-month low of $20.92 and a 12-month high of $30.43. The business's fifty day moving average price is $24.76 and its 200 day moving average price is $24.40. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion during the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the firm posted $0.60 EPS. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be paid a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 6.9%. Pfizer's dividend payout ratio is currently 91.49%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.